Company Overview
Snapshot
Founded in September 2008 by Prof. Avner Yayon, ProCore Bio Med operates with 1–10 employees. The company holds one patent, indicating its focus on proprietary technology in the health tech and life sciences sector.
Business overview
ProCore Bio Med is a biotechnology company focused on developing cost-effective solutions for bone and cartilage regeneration. Its core technology platform integrates proprietary scaffolds, growth factors, and stem or progenitor cells, utilizing a variety of biomaterials, including hyaluronic acid-based injectable hydrogels. The company's flagship product, RegenoGel, is a viscosupplement gel for treating osteoarthritis, designed to preserve joints and regenerate cartilage. ProCore Bio Med serves the healthcare industry, particularly in orthopedics, and operates within the biomaterials, medical technologies, and regenerative medicine sectors.
Log in to access full profile ›Company Intelligence Q&A
- What is ProCore Bio Med's primary focus?
- ProCore Bio Med primarily focuses on developing cost-effective solutions for cell and tissue regeneration, specifically targeting bone and cartilage regeneration.
- Who founded ProCore Bio Med?
- ProCore Bio Med was founded by Prof. Avner Yayon in September 2008.
- What is RegenoGel?
- RegenoGel is ProCore Bio Med's highly stable viscosupplement gel designed for treating osteoarthritis to preserve joints and regenerate cartilage. It is based on the company's proprietary HAProLink technology.
- What kind of technology platform does ProCore Bio Med utilize?
- ProCore Bio Med's technology platform includes a variety of biomaterials, such as hyaluronic acid-based injectable hydrogels, proprietary growth factors, and protocols for stem and progenitor cell isolation, expansion, and differentiation.
- In which consortium has ProCore Bio Med been a principal member?
- ProCore Bio Med has been a principal member of the Genesis consortium, the Israeli consortium for stem cell therapy, contributing its proprietary FGF variants and unique stem cell platform.